"/> Novus Biologicals™ Peptide bloquant d’anticorps AT… | B-LABO France

Novus Biologicals™ Peptide bloquant d’anticorps ATP13A2

Réf. : BL-RE-043514Réf. fabricant : 18107079 0.05 mg
132,83 € HT

Highly purified. Generating reliable and reproducible results. Applications: Antibody Competition

Gene ID (Entrez)
23400
Espèces
Human
Contenu et stockage
Store at -80 C. Avoid freeze-thaw cycles.
Formule
Peptide dissolved in dH2O. Contains no BSA.
À utiliser avec (application)
This Peptide is Useful as a Blocking Peptide for NB110-41486. IHC and WB Were Reported in Scientific Literature. For Further Blocking Peptide Related Protocol, Click Here .
Marque
Novus Biologicals

A peptide to ATP13A2. The ATP13A2 Blocking Peptide has been validated for the following applications: Antibody Competition.

Caractéristiques techniques

MarqueNovus Biologicals
Réf. B-LABOBL-RE-043514
Réf. fabricant18107079
Gene ID (Entrez)23400
EspècesHuman
Contenu et stockageStore at -80 C. Avoid freeze-thaw cycles.
FormulePeptide dissolved in dH2O. Contains no BSA.
À utiliser avec (application)This Peptide is Useful as a Blocking Peptide for NB110-41486. IHC and WB Were Reported in Scientific Literature. For Further Blocking Peptide Related Protocol, Click Here .
Alias de gèneATPase type 13A2, EC 3.6.3, EC 3.6.3.-, EC 3.6.3.5, EC 3.6.3.8, FLJ26510, HSA9947, KRPPD, PARK9putative ATPase, Parkinson disease (autosomal recessive) 9 (Kufor-Rakeb syndrome), probable cation-transporting ATPase 13A2
Symbole de gène(s)ATP13A2
Type de produitATP13A2
Quantité0.05 mg
État réglementaireRUO - research use only
Une question, une configuration particulière ?
Contactez-nous pour un devis.